At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMVT Immunovant, Inc.
Trading 04-02 11:56:42 EDT
15.91
+0.71
+4.67%
| High16.11 | Low14.90 | Vol1.88M |
| Open15.02 | D1 Closing15.20 | Amplitude7.94% |
| Mkt Cap2.70B | Tradable Cap992.07M | Total Shares169.86M |
| T/O29.51M | T/O Rate3.01% | Tradable Shares62.36M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?
Insider Monkey · 03-25
BUZZ-Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate
Reuters · 03-20
Buy Rating Affirmed for IMVT-1402: Promising Study Results and Strategic Focus in FcRn Space
TIPRANKS · 03-20
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Zacks · 03-20
Immunovant Is Maintained at Buy by B of A Securities
Dow Jones · 03-20
Immunovant price target lowered to $33 from $38 at BofA
TIPRANKS · 03-20
Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Dow Jones · 03-19
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Benzinga · 03-19
Immunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. Wainwright
TIPRANKS · 03-19
Immunovant Shares Down 5.2% After Late-Stage Data for Its Experimental Muscle Disorder Drug
THOMSON REUTERS · 03-19
Roivant says Immunovant announces results from Phase 3 study of batoclimab in MG
TIPRANKS · 03-19
Immunovant's muscle disorder treatment meets main goal in late-stage trial
Reuters · 03-19
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (Mg) and Chronic Inflammatory Demyelinating Polyneuropathy (Cidp) Studies
THOMSON REUTERS · 03-19
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Blockhead · 03-04
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts Offer Insights on Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
TIPRANKS · 03-03
Jefferies Initiates Immunovant at Hold With $20 Price Target
MT Newswires Live · 03-03
Immunovant initiated with a Hold at Jefferies
TIPRANKS · 03-02
Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts
Insider Monkey · 02-23
Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?
Insider Monkey · 02-22
Stifel Nicolaus Remains a Buy on Immunovant (IMVT)
TIPRANKS · 02-21
Introduction
Company Name.
Immunovant, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App